Seroatlas · Human Serome Atlas

TGFBR3

Transforming growth factor beta receptor type 3

Also known as: betaglycan, BGCAN, TGBR3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q03167
Gene
TGFBR3
Ensembl
ENSG00000069702
Chromosome
1
Canonical length
851 aa
Protein class
Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins
Subcellular location
Cytosol
Secretome location
Secreted to blood
Quaternary structure
Homodimer

OverviewNCBI Gene

This locus encodes the transforming growth factor (TGF)-beta type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.[provided by RefSeq, Sep 2010]

Canonical amino-acid sequenceUniProt

851 residues, UniProt reviewed canonical sequence.

>Q03167|TGFBR3
     1  MTSHYVIAIF ALMSSCLATA GPEPGALCEL SPVSASHPVQ ALMESFTVLS GCASRGTTGL
    61  PQEVHVLNLR TAGQGPGQLQ REVTLHLNPI SSVHIHHKSV VFLLNSPHPL VWHLKTERLA
   121  TGVSRLFLVS EGSVVQFSSA NFSLTAETEE RNFPHGNEHL LNWARKEYGA VTSFTELKIA
   181  RNIYIKVGED QVFPPKCNIG KNFLSLNYLA EYLQPKAAEG CVMSSQPQNE EVHIIELITP
   241  NSNPYSAFQV DITIDIRPSQ EDLEVVKNLI LILKCKKSVN WVIKSFDVKG SLKIIAPNSI
   301  GFGKESERSM TMTKSIRDDI PSTQGNLVKW ALDNGYSPIT SYTMAPVANR FHLRLENNAE
   361  EMGDEEVHTI PPELRILLDP GALPALQNPP IRGGEGQNGG LPFPFPDISR RVWNEEGEDG
   421  LPRPKDPVIP SIQLFPGLRE PEEVQGSVDI ALSVKCDNEK MIVAVEKDSF QASGYSGMDV
   481  TLLDPTCKAK MNGTHFVLES PLNGCGTRPR WSALDGVVYY NSIVIQVPAL GDSSGWPDGY
   541  EDLESGDNGF PGDMDEGDAS LFTRPEIVVF NCSLQQVRNP SSFQEQPHGN ITFNMELYNT
   601  DLFLVPSQGV FSVPENGHVY VEVSVTKAEQ ELGFAIQTCF ISPYSNPDRM SHYTIIENIC
   661  PKDESVKFYS PKRVHFPIPQ ADMDKKRFSF VFKPVFNTSL LFLQCELTLC TKMEKHPQKL
   721  PKCVPPDEAC TSLDASIIWA MMQNKKTFTK PLAVIHHEAE SKEKGPSMKE PNPISPPIFH
   781  GLDTLTVMGI AFAAFVIGAL LTGALWYIYS HTGETAGRQQ VPTSPPASEN SSAAHSIGST
   841  QSTPCSSSST A

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TGFBR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
64 nTPM

Expression across tissuesHPA

Tissue

  • ovary: 64 nTPM
  • adipose tissue: 62 nTPM
  • breast: 58 nTPM
  • placenta: 55 nTPM
  • cervix: 53 nTPM
  • urinary bladder: 46 nTPM

Single-cell type

  • podocytes: 1,800 nCPM
  • breast lactating cells: 826 nCPM
  • adrenal cortex cells: 626 nCPM
  • fibroblasts: 598 nCPM
  • myosatellite cells: 575 nCPM
  • fibro-adipogenic progenitors: 553 nCPM

Immune cell

  • gdT-cell: 35 nTPM
  • MAIT T-cell: 20 nTPM
  • memory CD8 T-cell: 19 nTPM
  • NK-cell: 17 nTPM
  • naive CD8 T-cell: 13 nTPM
  • memory CD4 T-cell: 8.9 nTPM

Brain region

  • choroid plexus: 43 nTPM
  • midbrain: 22 nTPM
  • thalamus: 18 nTPM
  • spinal cord: 18 nTPM
  • medulla oblongata: 18 nTPM
  • pons: 17 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.5
gnomAD pLI
0
gnomAD missense Z
1.21
DepMap mean gene effect
-0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TGFBR3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TGFBR3 as an antibody target. Whether an autoantibody or antibody against TGFBR3 could matter depends on whether native TGFBR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TGFBR3 is annotated at the cell surface, where native TGFBR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TGFBR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TGFBR3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...